Niki BioSolutions (NIKI)
Develops blood-based brain-health diagnostics and provides molecular biomarker testing services.
Something off on this page? Send us feedback.
Builds plasma-based molecular diagnostics for brain health and provides fee-for-service biomarker testing. Its platform combines organ-enriched microRNAs with genetic and protein markers, while proprietary tests remain pre-commercial.
Operates through DiamiR Biosciences, a blood-based molecular-diagnostics platform and clinical laboratory focused on brain health. Its APOE Genotyping test identifies variants, while CogniMIR is a plasma-based, non-invasive tool in development for Alzheimer’s and neurodegeneration risk assessment.
Generates observable revenue from fee-for-service biomarker work for biopharma customers, including microRNA expression, research-use protein assays, and genetic analysis. The clinical laboratory is in New Haven, Connecticut, alongside Princeton headquarters, and works with U.S. research, health-care, academic, foundation, and biopharma partners.
Combines organ-enriched microRNA intellectual property with genetic and protein markers in one laboratory workflow. It also retains Aptorum’s early-stage therapeutics in oncology and infectious disease. Clinical adoption depends on validation, laboratory credentials and approvals, reimbursement, funding, and reliable third-party testing operations.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $3.5M · Total debt $3.4M · Total assets $18.7M · Shareholders' equity $23.2M
- Revenue
- $0
- Operating income
- $0
- Net income
- −$307.5K
No dividends on record.
| Insiders2 holders · as of Aug 13, 2026 | 3.55% | 2.9K shares | |
| Otherremainder | 96.45% | 78.5K shares |
81.4K company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Justin Che Yuen WuInsiderdirector | 2.25% | 1,832 | Form 4filed Aug 13, 2026 ↗ |
Douglas Wayne ArnerInsiderdirector | 1.30% | 1,062 | Form 4filed Aug 13, 2026 ↗ |
Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Quest Diagnostics
National lab rival in Alzheimer's blood tests, APOE, and trial services.
- Labcorp
National lab rival with Alzheimer’s blood, APOE, and biopharma testing.
- Quanterix
Specialized blood-biomarker rival in Alzheimer’s LDTs and research services.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Niki BioSolutions | $7.00 | +5.90% | $538.3K | — | — | — | — |
| Quest Diagnostics | $241.00 | +0.08% | $26.58B | 25.6 | 21.0 | 2.3 | +10.2% |
| Labcorp | $330.80 | −0.28% | $27.20B | 27.4 | 17.5 | 1.9 | +5.8% |
| Quanterix | $2.53 | −3.07% | $122.9M | — | — | 0.8 | +34.6% |
| Median | 26.5 | 19.3 | 1.9 | +10.2% |